Southern Cross Pharma Ltd v Euro-Celtique S.A

Link copied
Case Copied 10 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 61

Patents:2002300863 & 2009243527

Title:Controlled Release Formulation

Patentee:  Euro-Celtique S.A.

Opponent:  Southern Cross Pharma Pty Ltd

Delegate:  Dr B. Akhurst

Decision Date:  21 September 2016

Hearing Date:  Written submissions filed on 23 August and 6 September 2016

Catchwords:  PATENTS – Final determination of oppositions to extensions of the term of two pharmaceutical patents – whether additional information provided by the patentee overcomes the deficiencies in the extension requests identified in the earlier decision – extensions granted.

Representation:  Counsel for the patentee: Philip Kerr.

Patent attorney for the applicant:  Allens Patent and Trade Mark Attorneys.

Patent attorney for the opponent: Duncan Bucknell Company.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2002300863 & 2009243527

Title:Controlled Release Formulation

Patentee:  Euro-Celtique S.A.

Date of Decision:  21 September 2016

DECISION

The further information provided by Euro-Celtique S.A overcomes the deficiencies identified in the earlier decision published as Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1.

Subject to an appeal of this decision, I grant the extensions to the term of patents 2002300863 and 2009243527.

REASONS FOR DECISION

  1. This matter concerns the final determination of applications by Euro-Celtique S.A. to extend the term of patents 2002300863 and 2009243527 and the oppositions by Southern Cross Pharma Pty Ltd.  The date of these patents is 9 May 1994 and their maximum 20-year term expired on 9 May 2014.  If extensions are granted the term of each patent would be extended until 21 September 2015.

    Background

  2. On 7 May 2014, Euro-Celtique S.A. (the patentee) applied to extend the term of three patents including 2002300863 (‘863) and 2009243527 (‘527).  On 10 September 2014, Southern Cross Pharma Pty Ltd (the opponent) opposed grant of the extensions.  The matters were heard and in Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1 (the earlier decision), I found the oppositions to extend the term of patents ‘863 and ‘527 were successful due to deficiencies in the extension requests.  However, I allowed the patentee a period of time to provide further information in order to overcome the deficiencies.  

  3. As the basis for its extension request, the patentee relied on the product Tramal® SR 100, which was developed by Grunenthal GmbH and is manufactured by them under licence from the patentee.  Thus, on 15 February 2016 the patentee advised that the further information it sought to file was proprietary and confidential and as a consequence it requested a confidentiality order.  The opponent requested a hearing and in Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 44, the Deputy Commissioner directed under reg 4.3(2)(b) that the patentee’s evidence containing the further information, when filed, should not be open to inspection, but it would be available for inspection by the opponent subject to specified conditions. The patentee subsequently filed the further information on 17 August 2016. Note that the information in this decision which is subject to…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Southern Cross Pharma Ltd v Euro-Celtique S.A and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] APO 61
Decision Date

CaseChat Overview and Summary

Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 61 involves the final determination of applications by Euro-Celtique S.A. to extend the term of patents 2002300863 and 2009243527 for controlled release formulations. Southern Cross Pharma Pty Ltd opposed the grant of these extensions, leading to a hearing before the Australian Patent Office. The patents in question had expired on 9 May 2014, but the applications sought to extend their terms until 21 September 2015. The primary legal issue before the court was whether the additional information provided by Euro-Celtique S.A. sufficiently addressed the deficiencies previously identified in the earlier decision, thereby justifying the grant of the patent term extensions.

The court considered the specific requirements for patent term extensions under sections 70 and 71 of the relevant Act, as well as Regulation 6.8 and Regulation 6.11. Section 70 sets out the conditions for the extension of a patent term, while section 71 prescribes the form and timing of an application. Regulation 6.8 mandates the information required to accompany an application for extension of the term of a standard patent, and Regulation 6.11 allows for the Commissioner to request further information if the application is deficient.

The court noted that in the earlier decision, it had found the oppositions to the extensions of patents 2002300863 and 2009243527 to be successful due to deficiencies in the extension requests. Specifically, the patentee had not provided the weight-for-weight proportions of certain ingredients in the pharmaceutical product TRAMAL® SR 100. The patentee was then given an opportunity to provide further information to overcome these deficiencies. The further information included detailed weight-for-weight percentages of the polymers and other ingredients in TRAMAL® SR 100, demonstrating that the product met the requirements set forth in the patent claims.

After reviewing the additional information, the court concluded that the further information provided by Euro-Celtique S.A. adequately addressed the deficiencies identified in the earlier decision. The court found that the TRAMAL® SR 100 product contained the necessary ingredients in the required proportions, thereby satisfying the conditions for the patent term extensions. As a result, the court granted the applications to extend the term of patents 2002300863 and 2009243527, subject to any potential appeal of this decision.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.